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Identifying determinants of NADPH specificity in Baeyer–Villiger
monooxygenases
Nanne M. Kamerbeek, Marco W. Fraaije and Dick B. Janssen
Laboratory of Biochemistry, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, the Netherlands
The Baeyer–Villiger monooxygenase (BVMO), 4-hydroxy-
acetophenone monooxygenase (HAPMO), uses NADPH
andO2 to oxidize a variety of aromatic ketones and sulﬁdes.
The FAD-containing enzyme has a 700-fold preference for
NADPH over NADH. Sequence alignment with other
BVMOs, which are all known to be selective for NADPH,
revealed three conserved basic residues, which could account
for the observed coenzyme speciﬁcity. The corresponding
residues in HAPMO (Arg339, Lys439 and Arg440) were
mutated and the properties of the puriﬁed mutant enzymes
were studied. For Arg440 no involvement in coenzyme
recognition could be shown as mutant R440A was totally
inactive. Although this mutant could still be fully reduced
by NADPH, no oxygenation occurred, indicating that
this residue is crucial for completing the catalytic cycle of
HAPMO. Characterization of several Arg339 and Lys439
mutants revealed that these residues are indeed both
involved in coenzyme recognition.Mutant R339A showed a
largely decreased aﬃnity for NADPH, as judged from kin-
etic analysis and binding experiments. Replacing Arg339
also resulted in a decreased catalytic eﬃciency with NADH.
Mutant K439A displayed a 100-fold decrease in catalytic
eﬃciency with NADPH,mainly caused by an increasedKm.
However, the eﬃciency with NADH increased fourfold.
Saturation mutagenesis at position 439 showed that the
presence of an asparagine or a phenylalanine improves the
catalytic eﬃciency with NADH by a factor of 6 to 7. All
Lys439 mutants displayed a lower aﬃnity for AADP+,
conﬁrmingaroleof the lysine in recognizing the2¢-phosphate
of NADPH. The results obtained could be extrapolated
to the sequence-related cyclohexanone monooxygenase.
Replacing Lys326 in this BVMO, which is analogous to
Lys439 inHAPMO, again changed the coenzyme speciﬁcity
towards NADH. These results indicate that the strict
NADPH dependency of this class of monooxygenases is
based upon recognition of the coenzyme by several basic
residues.
Keywords: 4-hydroxyacetophenone monooxygenase; ﬂavo-
protein; Baeyer–Villiger monooxygenase; NADPH; coen-
zyme speciﬁcity.
An intriguing phenomenon in enzymology is the discrim-
ination that pyridine nucleotide-dependent enzymes can
make between NADP(H) and NAD(H). The only differ-
ence between these two molecules is a phosphate group
esteriﬁed with the 2¢-hydroxyl group of the adenosine
ribose. Phosphorylation of NAD+, yielding NADP+, is
catalyzed by NAD kinase [1]. This allosteric enzyme,
inhibited by NADPH and NADH, is thought to be the
key enzyme in regulating the NAD+ and NADP+ levels in
living cells. In general, oxidative degradation pathways use
NAD+ as an electron acceptor, whereas reductive biosyn-
thesis routes primarily use NADPH as a source of reducing
equivalents [2]. For biodegradation of xenobiotic com-
pounds, this general rule is not valid as the monooxygenases
and dioxygenases involved can be both NADPH and
NADH speciﬁc.
NAD(P)(H)-dependent enzymes are ubiquitous, and,
from a large number of X-ray structures, more than 10
different NAD(P)(H) binding folds can be identiﬁed, of
which the Rossmann-fold is the most common [3]. A recent
study of enzyme–NAD(P)(H) complexes showed that the
binding fold also correlates with the conformation of the
NAD(P)(H) ligand [4]. The afﬁnity for NAD(P)(H) can
range from very tight binding, as in nicotinoproteins, which
use the nucleotides as a cofactor [5], to weak binding, as is
the case for p-hydroxybenzoate hydroxylase, an enzyme
that does not have a recognizable NAD(P)H-binding
domain [6]. Although most enzymes are speciﬁc for one
of the pyridine nucleotide coenzymes, there are also
enzymes that display a dual speciﬁcity. For example,
glutamate dehydrogenases form a family whose members
have a speciﬁcity range from strict NADP+ to strict
NAD+, including members that can use either coenzyme
[7,8].
The molecular basis for coenzyme speciﬁcity has been
studied for different classes of enzymes [9–14]. Furthermore,
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examples of successful reversal of coenzyme speciﬁcity have
been described formembers of the dehydrogenase/reductase
families (e.g. glutathione reductase [15], isopropyl-malate
dehydrogenase [16], lactate dehydrogenase [17], formate
dehydrogenase [18] and 2,5-diketo-D-gluconic acid reduc-
tase [19]). All of these enzymes contain a well-deﬁned
NADPH-binding domain. Recently, a reversal of coenzyme
speciﬁcity for p-hydroxybenzoate hydroxylase, a member of
the NAD(P)H-dependent ﬂavoprotein aromatic hydroxy-
lases, was also established [20]. In general, the removal
or introduction of basic residues that interact with the
2¢-phosphate of NADP(H), in combination with other
mutations, is important for conversion of the coenzyme
speciﬁcity [21].
Baeyer–Villiger monooxygenases (BVMOs) are ﬂavo-
protein monooxygenases that catalyze the conversion of a
ketone into an ester or of a cyclic ketone into a lactone
[22]. They are involved in oxidative degradation proces-
ses and biosynthesis of secondary metabolites, such as
aﬂatoxin. The electrons required for catalyzing Baeyer–
Villiger reactions are delivered by NADH or NADPH.
BVMOs have been classiﬁed into two groups: Type I
BVMOs contain FAD as a cofactor and use NADPH as
the coenzyme, whereas Type II BVMOs are dependent on
FMN and NADH [23]. While no Type II BVMO has
been cloned, the number of cloned and characterized
Type I BVMOs is steadily increasing [22]. Annotation
of novel Type I BVMO sequences from the genome
databases is possible using a speciﬁc sequence motif [24],
and diverse PCR-based techniques provide tools to
identify putative BVMOs from unsequenced organisms
[25,26]. Type I BVMO sequences contain two dinucleo-
tide-binding sequence motifs (Rossmann-fold motifs) –
GxGxxG – which are involved in binding of the ADP
moieties of FAD and NADPH [27]. This distinguishes
them from another class of ﬂavin-containing monooxy-
genases – the mechanistically related aromatic hydroxy-
lases (such as p-hydroxybenzoate hydroxylase) – which
contain only one dinucleotide-binding domain for FAD
binding [6]. The overall sequence organization in Type I
BVMOs is similar to the organization in the NAD(P)H-
dependent disulﬁde reductases [28], and is also found in
two other ﬂavoprotein monooxygenase families, namely
ﬂavin-containing monooxygenases (FMOs) and N-hy-
droxylating monooxygenases (NMOs). Type I BVMOs,
FMOs and NMOs have been shown to form one
superfamily [24]. The individual members of this mono-
oxygenase superfamily are all single-component, FAD-
containing enzymes and prefer NADPH as the electron
donor. At present, there is no structure known of any
BVMO, FMO or NMO.
BVMOs are of industrial interest as they show broad
substrate speciﬁcities and high enantio- and regioselective
conversions [22,23,29,30]. The most extensively studied
BVMO, cyclohexanone monooxygenase (CHMO), has
been shown to convert over 100 unnatural substrates. This
has fuelled a biotechnological interest in this class of
monooxygenases. For isolated enzyme applications, a
change of an NADPH-speciﬁc BVMO towards an NADH
utilizing enzyme is economically attractive, as NADH is
less expensive and more stable than NADPH. To circum-
vent expensive coenzyme recycling, whole-cell conversions,
using recombinant Escherichia coli, are often favored for
enzyme-mediated oxygenating reactions [31,32]. Also for
these whole-cell conversions, BVMOs that (also) accept
NADH as a coenzyme would be beneﬁcial for catalytic
efﬁciency, as E. coli contains high levels of NADH [33].
Until the present study, no BVMO had been investigated
to identify amino acids responsible for its coenzyme
speciﬁcity.
Recently, we cloned the gene encoding 4-hydroxyaceto-
phenone monooxygenase (HAPMO) from Pseudomonas
ﬂuorescensACB into E. coli. The enzyme, a 145 kDa dimer
containing one FAD molecule per subunit, efﬁciently
catalyzes Baeyer–Villiger oxidation reactions on various
ketones. Besides Baeyer–Villiger oxidations, the enzyme
also catalyzes highly enantioselective sulfoxidations with the
use of NADPH [34]. In a previous study where we analyzed
the primary HAPMO sequence, we identiﬁed an arginine
(Arg339) that was strictly conserved among the known
Type I BVMOs [35]. This arginine is located close to the
C-terminal Rossmann-fold motif, which is involved in
NADPHbinding.We suggested that this residue is involved
in the recognition of NADPH, as it also aligns with a
conserved basic residue in yeast FMO (Lys219) that was
shown to contribute to coenzyme recognition [36]. In the
present work we explored, by site-directed mutagenesis,
whether Arg339 is involved in coenzyme recognition by
HAPMO. Two other conserved basic amino acids were also
examined regarding their contribution to coenzyme specif-
icity. In addition, another BVMO (CHMO) was included in
this site-directed mutagenesis study.
Materials and methods
Chemicals
NADPH, NADH, NADP+, 3-aminopyridine adenine
dinucleotide phosphate (AADP+), 3-acetylpyridine adenine
dinucleotide phosphate (acetyl-NADP+), thionicotinamide
adenine dinucleotide phosphate (thio-NADP+), 4-hydroxy-
acetophenone, cyclohexanone, and L(+)-arabinose were
obtained from Sigma-Aldrich.
Strains and plasmids
E. coli TOP10 cells were obtained from Invitrogen. For
expression of HAPMO in E. coli TOP10 cells, a pBAD/
myc-HisA vector (Invitrogen) with a uniqueNdeI site at the
start of translation was created (pBADN). For this, the two
original NdeI sites were deleted by mutating the guanine
base of the CATATG NdeI recognition sequence into a
cytosine, and the unique NcoI site at the translation start
was changed into a unique NdeI site by replacing the ACC
sequence in front of the start codon by CAT. These
mutations were introduced using the Quick-change site-
directed mutagenesis kit from Stratagene. The hapE gene
was cloned into NdeI and BglII digested pBADN yielding
pBAD/hapE. E. coli TOP10, harboring plasmid pQR239
encoding the cyclohexanone monooxygenase from Acineto-
bacter sp. NCIB 9871 [38], was kindly provided by J. Ward
(University College London). Cells were grown in Luria–
Bertani (LB) broth supplemented with ampicillin
(100 lgÆmL)1) (LBamp).
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Site-directed and random mutagenesis
The Quick-change site-directed mutagenesis kit from Strat-
agene was used for the construction of mutants, using the
plasmid pBAD/hapE as template and the following muta-
genic primers (the letters f and r, at the end of the primer
name denote forward or reverse primer, respectively):
PR339Af, 5¢-GAAGGTCTTTGCGGCGACCACCAA
CTG-3¢ and PR339Ar, 5¢-CAGTTGGTGGTCGCCGC
AAAGACCTTC-3¢; PK439Af, 5¢-CCTGTCGGCGGT




CGCCGAC-3¢. The underlined bases indicate the bases that
were altered to create an alanine codon.
For saturation mutagenesis at position 439, a modiﬁed
procedure of Stratagene was followed. After the ﬁrst
transformation of the E. coli TOP10 cells with the PCR
mixture, the resulting colonies were pooled and their
plasmids isolated. These plasmids were used for an
additional transformation step to remove hybrid plas-
mids. The following primers were used: PK439XfII,
5¢-CCTGTCGGCGGTNN(G/C)CGCATCGTACGAG-3¢
and PK439XrII, 5¢-CTCGTACGATGCG(G/C)NNAC
CGCCGACAGG-3¢. Transformants were picked and
grown overnight in 96-well plates containing LBamp +
10% (v/v) glycerol and then stored at )80 C until required.
The mutation K326A in CHMO was created using
the primers PK326Af, GATTTGTATGCAGCGCGTC
CGTTGTG and PK326Ar, CACAACGGACGCGCTGC
ATACAAATC (the underlined bases indicate the bases
altered to create an alanine codon) and pQR239 [38] as
template.
Screening of the saturation mutagenesis library
The 200 clones from the library were cultured individually
overnight at room temperature in tubes containing 5 mL
of LBamp + 0.002% (w/v) arabinose. After harvesting
by centrifugation, the cells were resuspended in 0.5 mL of
potassium phosphate buffer (pH 7.5), then sonicated and
centrifuged to produce cell-free extract (CFE). NADPH
or NADH consumption by CFE in the presence of
4-hydroxyacetophenone was monitored for 5 min at
370 nm using a plate reader (Bio-Tek instruments). Per
well, the reaction mixtures were as follows: 190 lL of
potassium phosphate buffer (pH 7.5), 400 lM 4-hydroxy-
acetophenone, 1 mM NADPH or NADH, and 10 lL of
CFE. The reaction was started by the addition of CFE. The
protein content of the CFEs was measured using the
Bradford assay [39].
Expression and purification of wild-type HAPMO
and mutant enzymes
E. coli TOP10 cells containing the plasmids with the
mutated genes were precultured in 30 mL of LBamp for
6–8 h at 30 C. The preculture was used to inoculate 1 L
of LBamp + 0.002% (w/v) arabinose. The cells were
grown overnight at 20 C to a ﬁnal attenuance (D), at
600 nm, of 2–3, and harvested by centrifugation. Further
puriﬁcation steps were performed as described previously
[35]. HAPMO concentrations were determined spectro-
photometrically using a molar extinction coefﬁcient
of 12.4 mM)1Æcm)1 at 439 nm for protein-bound FAD
[35].
Expression and purification of wild-type CHMO
and mutant enzymes
E. coli TOP10 cells, containing plasmid pQR239 or plasmid
pQR239/K326A, were precultured in 30 mL of LBamp for
6–8 h at 30 C. The preculture was used to inoculate 1 L
of LBamp + 0.01% (w/v) arabinose. The cells were grown
overnight at 37 C, harvested by centrifugation and resus-
pended in 20 mMpotassium phosphate buffer, pH 7.2. Cells
were sonicated and then centrifuged (15 000 g for 30 min at
4 C). Subsequently, CHMOwas partially puriﬁed from the
cell-free extract using two chromatography steps. The
supernatant was loaded onto a Hi-prep 16/10Q XL
DEAE-sepharose (50 mL) column (Pharmacia) that was
pre-equilibrated with 20 mM potassium phosphate buffer
containing 1 mMmercaptoethanol. Protein was eluted from
the column with a linear gradient of 0–0.5 M KCl in 20 mM
phosphate buffer, pH 7.2, in ﬁve column volumes. Frac-
tions containing CHMO activity were pooled and concen-
trated using an Amicon ﬁltration unit equipped with a
30 kDa cut-off ﬁlter. Concentrated protein was applied on a
Superdex 200 26/60 size-exclusion column (Pharmacia). The
protein was eluted with 20 mM potassium phosphate buffer,
pH 7.2, containing 1 mM mercaptoethanol. Fractions con-
taining CHMO activity were pooled and concentrated. The
CHMO concentration was determined using an extinction
coefﬁcient of 13.8 mM)1Æcm)1 at 440 nm [40].
Protein and activity assays
All HAPMO activity measurements were performed in air-
saturated 50 mM potassium phosphate buffer, pH 7.5. The
Michaelis–Menten constants, kcat andKm, for NADPH and
NADH were determined by varying the concentrations of
the coenzyme in the presence of 100 lM 4-hydroxyaceto-
phenone. Enzyme activities were determined spectro-
photometrically at 25 C by following, at 370 nm, the
absorbance decrease caused by NAD(P)H oxidation
(e370 ¼ 2.7 mM)1Æcm)1). In the case of high Km values for
NADPH and/or NADH, the absorbance decrease was
followed at 390 nm (e390 ¼ 0.43 mM)1Æcm)1).
CHMO activity was determined by monitoring the
oxidation of NADPH upon conversion of 100 lM cyclo-
hexanone in 0.1 M glycine/NaOH, pH 9.0.
AADP+ titrations
UV/Vis spectra were acquired at 25 Cusing a Perkin Elmer
Lambda Bio40 spectrophotometer. Aliquots of the concen-
trated AADP+ solution were added to the enzyme solution
until saturation was observed. Absorbance changes were
plotted as difference spectra and, from these spectra, the
changes at selected wavelengths were used to calculate the
binding stoichiometry at each step of the titration. As
AADP+ also absorbs, to some extent, up to 400 nm,
absorbance differences were typically taken from the
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450–500 nm region. From these data, the binding constants
were obtained using Eqn (1).
Kd ¼ ½Efree ½AADPfree½EAADP ð1Þ
Flavin-monitored turnover of HAPMO
The redox state of the ﬂavin cofactor during catalysis was
monitored on an Applied Photophysics SX17MV stopped-
ﬂow instrument. All concentrations stated are those in
the reaction chamber after mixing. For ﬂavin-monitored
turnover of HAPMO, equal amounts of air-saturated
enzyme solution (10 lM) and substrate solution in 50 mM
phosphate buffer, pH 7.5, containing 1.5 or 3 mM
NADPH, with or without 500 lM 4-hydroxyacetophenone,
were mixed. The redox state of the ﬂavin was monitored,
at 439 nm, over a 10 s timespan. The difference between
the absorbance of FADox and FADred, determined by
mixing wild-type enzyme with buffer, without or with
NADPH, respectively, was set as 100% oxidized FAD.
When mutants could not be reduced completely in the
presence of NADPH alone, the ratio of absorbance for
FADox and FADred from wild-type HAPMO (WT-
HAPMO) was used to calculate the FADred absorbance
for the mutant.
Results
Coenzyme specificity and coenzyme analogue binding
for WT-HAPMO
HAPMO has a 700-fold preference for NADPH over
NADH, as expressed by the ratio (kcat/Km(NADPH))/(kcat/
Km(NADH)) (Table 1). To gain further insight into the
coenzyme afﬁnity of WT-HAPMO, we attempted to
measure NADP+ binding spectrophotometrically. It was
expected that binding of NADP+ would position the
nicotinamide ring close to the oxidized isoalloxazine ring of
the FAD cofactor. This change in the microenvironment of
the cofactor is typically reﬂected by changes in the ﬂavin
spectral properties, as observed for NADP+ binding to
CHMO [40]. Such a change would allow us to determine
the dissociation constant for NADP+. Remarkably,
WT-HAPMO did not show any perturbation of the ﬂavin
spectrum upon NADP+ addition up to a concentration of
1.2 mM. This shows that NADP+ is not binding, or at least
not close to, the isoalloxazine moiety of the FAD. NADP+
at a concentration of 500 lM did not inhibit HAPMO
activity in the presence of 200 lM NADPH, indicating that
the oxidized coenzyme does not compete strongly with its
reduced form (Table 2).
In order to identify a suitable probe for coenzyme
binding, three NADP+ analogues were tested for their
ability to inhibit HAPMO catalysis. Their structures differ
from each other only in carrying different substituents
on the positively charged nicotinamide ring (Fig. 1). From
these compounds, only AADP+ was found to be a very
effective inhibitor, as 5 lMAADP+was sufﬁcient to inhibit
HAPMO activity by 80% (Table 2). This suggests that the
substitutions on the 3-position of the pyridine ring are
crucial for coenzyme binding. In contrast to NADP+,
titration of oxidized HAPMO with AADP+ resulted in
considerable changes to the ﬂavin spectrum (Fig. 2). The
absorbance change at 480 nm was used to calculate the
dissociation constant (Kd) of AADP
+. The strong inhibi-
Table 1. Kinetic analysis of wild-type 4-hydroxyacetophenone monooxygenase (WT-HAPMO), HAPMO mutants, WT cyclohexanone mono-
oxygenase (CHMO) and CHMO mutant K326A.
kcat (s












N + H %NADPH NADH NADPH NADH NADPH NADH
HAPMO
WT 10.1±0.1 1.7±0.2 12±0.6 1440±140 840 1.2 700 0.4 0 46
R339A >0.1 0.19±0.1 >3000 3000±1860 0.0003 0.063 4.8 · 10)3 >50 77 96
K439A 1.6±0.1 2.4±0.1 200±51 520±80 8 4.6 1.7 2.1 25 38
K439F 1.0±0.1 2.4±0.2 80±18 300±80 13 8 1.7 2.5 20 50
K439P 0.2±0.01 0.7±0.1 17±3.5 1280±290 12 0.5 24 1.8 73 80
K439N 3.5±0.2 5.1±0.2 78±10 780±75 45 7 6 2.5 1 46
R440A – – – – <0.0001 <0.0001 – 0.1 3 3
CHMO
WT 14±0.5 1.4±0.1 7.3±1.4 420±80 1900 3.3 576
K326A 3.7±0.2 0.5±0.1 160±30 230±100 23 2.2 10
a FADox + N indicates the percentage of oxidized cofactor present during the steady-state turnover of NADPH only.
b FADox+N+H
indicates the percentage of oxidized cofactor present during steady-state turnover of NADPH in the presence of 4-hydroxyacetophenone.
Table 2. Inhibition of 4-hydroxyacetophenone monooxygenase
(HAPMO) activity by NADPH analogues. Activity was measured
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tion by AADP+ is reﬂected by its low Kd, of only 0.4 lM
(Table 1). Hence, AADP+ was chosen as a probe to
determine the coenzyme afﬁnity of the HAPMO variants.
As mutagenesis of residues involved in binding of the
coenzyme could also affect the efﬁciency of ﬂavin reduction,
WT-HAPMO was ﬁrst studied to obtain insight into the
equilibrium between reduced and oxidized FAD during
steady-state catalysis. For this, the redox state of the ﬂavin
was followed spectrophotometrically during turnover. As
expected, WT-HAPMO was completely reduced upon
mixing with NADPH only. In the presence of 4-hydroxy-
acetophenone, the ratio FADox/FADred during turnover
was  1 : 1 (Table 1), suggesting a balance between the
reductive and oxidative half-reactions.
Mutagenesis of conserved residues and characterization
of the mutants
In order to identify amino acids that could account for the
strict NADPH speciﬁcity, the HAPMO sequence was
aligned with the sequences of other characterized Type I
BVMOs (Fig. 3). The sequence-related yeast FMOwas also
included because the conserved arginine of Type I BVMOs
(HAPMO R339), aligns with Lys219 of yeast FMO, a
residue known to be involved in NADPH recognition [36].
Furthermore, part of the sequence of theE. coli thioredoxin
reductase (TrxR), for which the structure has been deter-
mined, could be aligned. The crystal structure of E. coli
TrxR, in complex with AADP+ (Protein Data Bank entry
1F6M), has revealed that residues Arg177 and Arg182
interact with the 2¢-phosphate moiety of the NADPH
analogue [41]. As shown in Fig. 3, HAPMO R339 aligns
with TrxRR177. There is no obvious HAPMO counterpart
for TrxR Arg182. Usually, the 2¢-phosphate interacts with
two or three basic residues in combination with a serine or
another amino acid containing an OH-group [20,42]. Two
additional conserved basic residues, which might contribute
to this, were identiﬁed in the BVMO sequences (HAPMO
Lys439 and Arg440).
To study the involvement of Arg339, Lys439 and Arg440
in coenzyme speciﬁcity, these positively charged amino acids
were individually replaced with an alanine. All variants
appeared as dimers upon puriﬁcation and contained one
FAD per enzyme monomer, as derived from the ratio A280/
A440. Apparently, the mutations do not affect dimerization
and FAD binding. To examine the effect of the mutations
on coenzyme speciﬁcity, the kcat andKm values for NADPH
and NADH were determined and compared with those of
WT-HAPMO (Table 1).
Properties of R339A. Replacement ofArg339with alanine
had a dramatic effect on catalysis. The speciﬁcity shifted
150 000-fold towards NADH. However, this shift was
mainly caused by an almost complete loss of activity with
NADPH and not by improvement of activity with NADH.
WhereasWT-HAPMOdisplays a high afﬁnity forAADP+,
titrationof theR339Aenzymewithup to50 lMAADP+did
not lead to signiﬁcant spectral perturbation of the FAD
Fig. 1. Structures of NADPH, NADP+ and
NADP+ analogues.
Fig. 2. AADP+ titration of 4-hydroxyacetophenone monooxygenase
(HAPMO). Spectra are shown of HAPMO K439A (6.2 lM) in the
presence of 0, 3.4, 6.7, 10.0, 16.7 and 33.0 lMAADP+. The increase in
absorbance at  350 nm is mainly the result of AADP+ absorbance.
Absorbance changes at higher wavelengths are indicative of ligand
binding. The inset shows the diﬀerence spectrum between uncom-
plexed enzyme and the spectrum obtained after addition of 13.4 lM
AADP+.
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spectrum. This low afﬁnity forAADP+ is in agreement with
the observed high Km value for NADPH for R339A, being
>3 mM. Next, mutant R339A was studied using ﬂavin-
monitored turnover experiments to examine whether coen-
zyme recognition is indeed limiting catalysis.Mixing R339A
with NADPH, in the presence or absence of 4-hydroxyac-
etophenone, showed that the majority of FAD is in the
oxidized state during turnover. This suggests that NADPH-
mediated ﬂavin reduction is rate limiting for this mutant.
Properties of K439A. The K439A mutation resulted in a
400-fold improvement of preference towards NADH. This
was mainly caused by an increased Km for NADPH. The
reduced recognition of NADPH was also reﬂected in a
higherKd of AADP
+ for K439A. Interestingly, except for a
decreased efﬁciency with NADPH, an improvement of
catalytic efﬁciency with NADH was also observed. Muta-
genesis of Lys439 did not drastically change the balance
between reduced and oxidized ﬂavin during steady-state
turnover, indicating that the reactivity with the ﬂavin is not
impaired by this mutation.
Properties of R440A. Mutagenesis of Arg440 resulted in a
drastic effect on catalysis, with no signiﬁcant activity being
observed for this mutant (Table 1). To our surprise, the
R440A mutant showed slightly enhanced binding of
AADP+ compared with WT-HAPMO. The inactivity of
this mutant suggests that NADPH could still bind to this
mutant, but that the reduction of FAD or subsequent steps
were impaired, preventing turnover. The ﬂavin-monitored
turnover data showed that R440A could indeed be fully
reduced by NADPH (Table 1). However, in the presence of
the aromatic substrate, all the ﬂavin remained in the reduced
state, indicating that subsequent steps towards oxygenation
are impaired. Together, these results show that Arg440 is
not important for coenzyme recognition, but plays an
important role in catalysis.
Saturation mutagenesis on K439
The site-directed mutagenesis study revealed that Lys439 is
an attractive target for mutagenesis to change the HAPMO
coenzyme preference towards NADH. To investigate whe-
ther the improved efﬁciency with NADH, obtained with
K439A, could be further improved by substitution with
other amino acids, it was decided to perform saturation
mutagenesis to create every possible amino acid substitution
at position 439. From a library of 200 clones, CFEs were
prepared and measured for their speciﬁc activities with
NADPH and NADH. As controls, CFEs of E. coli
expressing WT-HAPMO and K439A were included in
these experiments.
Interestingly, almost half of the 200 clones (48%) showed
a higher activity with NADH compared to WT-HAPMO,
and 19% of the clones displayed an activity within the
K439A range (Fig. 4). Four clones with increased activity
relative to K439A were sequenced, and three different
substitutions –K439F,K439P andK439N–were identiﬁed.
The three mutants were puriﬁed and tested for their kinetic
parameters (Table 1). The K439P mutant was apparently
false-positive, as it showed similar Km values but signiﬁ-
cantly lower kcat values with both coenzymes compared
to WT-HAPMO. As expected, both K439F and K439N
displayed improved catalytic efﬁciencies with NADH.
Mutant K439F showed a similar shift in coenzyme prefer-
ence asK439A comparedwithWT-HAPMO.However, the
K439F mutant displayed relatively low Km values for both
NADPH and NADH, resulting in relatively high catalytic
efﬁciencies for both coenzymes. Compared to the K439A
and K439F mutants, the K439N variant displayed a
relatively high kcat value withNADH (5.1 s
)1), approaching
the kcat of WT-HAPMO with NADPH (10.1 s
)1).
In line with the increased Km values for NADPH, the Kd
values for AADP+ of all three Lys439 variants increased
signiﬁcantly when compared with WT-HAPMO (Table 2).
Fig. 3. Partial alignment of cloned Type I
Baeyer–Villiger monooxygenases (BVMOs),
yeast ﬂavin-containing monooxygenase (FMO)
and Escherichia coli thioredoxin reductase. The
arrows indicate the mutated amino acids.
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This again conﬁrms a role of Lys439 in coenzyme binding.
By monitoring the redox state of the ﬂavin during turnover
of NADPH, it was found that the different amino acid
substitutions at position 439 have different effects on the
efﬁciency of ﬂavin reduction by NADPH. Only the K439N
mutant was fully reduced by NADPH. In the presence of
4-hydroxyacetophenone and NADPH, it was found that
the K439A/F/N mutants showed [FADox]/[FADred] ratios
of around 1/1 during steady-state catalysis, which is also the
case forWT-HAPMO. TheK439Pmutant was less efﬁcient
in the reductive half-reaction, while it was able to bind
NADPH, as evidenced by AADP+ binding. This suggests
that with this HAPMO variant, NADPH binding is
perturbed in such a way that hydride transfer is impaired.
This is also reﬂected in the low kcat values observed for this
mutant. Apparently all other engineered Lys439 mutants
are still able to bind the coenzyme in such a way that the
nicotinamide ring is correctly positioned to facilitate ﬂavin
reduction, resulting in acceptable kcat values.
K326A mutation in CHMO
As mutating the conserved Lys439 in HAPMO drastically
changed the recognition of coenzyme, it was expected that a
similar effect could be obtained when mutating an analog-
ous residue in another Type I BVMO. To test this
hypothesis, Lys326 in CHMO was mutated to alanine.
Kinetic analysis of the K326A mutant again revealed a
signiﬁcant shift in coenzyme speciﬁcity towards NADH
(Table 2). As with HAPMO, the catalytic efﬁciency with
NADPH was reduced by two orders of magnitude, mainly
owing to an increasedKm for NADPH. In contrast with the
results obtained with HAPMO K439A, there was also a
slight decrease in the catalytic efﬁciency with NADH.
Nevertheless, these results conﬁrmed our ﬁnding that the
respective conserved lysine in Type I BVMOs is involved in
recognition of the coenzyme.
Discussion
BVMOs are ﬂavin-containing monooxygenases that cata-
lyze NAD(P)H-dependent oxygenations of a variety of
substrates. Two classes of BVMOs have been described:
Type I BVMOs, which are FAD and NADPH dependent;
and Type II BVMOs, which are FMN and NADH
dependent. The current report describes a mutagenesis
study of three basic residues within the Type I BVMO class,
in order to elucidate their possible role in coenzyme
recognition.
Sequence analysis has shown that HAPMO contains two
Rossmann-fold domains; one is responsible for FAD
binding (N-terminal domain) and the other is responsible
for binding the coenzyme, NADPH (C-terminal domain).
HAPMO, showing a 700-fold preference for NADPH over
NADH, contains a conserved arginine (Arg339), located
19 residues after the C-terminal Rossmann-fold motif
(GxGxxG). It was shown by Suh et al. that mutation of
the homologous Lys219, in the distantly related yeast ﬂavin-
dependent monooxygenase, to an alanine, resulted in a
90-fold reduction of activity with NADPH, whereas the
activitywithNADHwasunaffected[36].ChangingHAPMO
Arg339 to alanine had a detrimental effect on the catalytic
efﬁciency with NADPH, as it showed a decrease of six
orders of magnitude. In fact, the Km for NADPH could not
be determined, as no saturation behavior was observed at
the concentrations measured, suggesting loss of coenzyme
recognition. This was supported by the dramatically
decreased afﬁnity of the NADP+ analogue, AADP+.
Activity with NADH was also impaired, but to a lesser
extent (20-fold). From these results it can be concluded that
Arg339 in HAPMO is crucial for coenzyme binding.
Besides arginines, also lysines are often found to interact
with the 2¢-phosphate group of NADPH [43–46]. We have
found that the conserved lysine, at HAPMO position 439,
clearly contributes to the discrimination between NADPH
and NADH. The introduction of an alanine at this position
allows improved catalytic performance with NADH, while
the catalytic efﬁciencywithNADPH is signiﬁcantly affected.
Replacing the analogous lysine (Lys329) in another Type I
BVMO, CHMO, again resulted in a shift of coenzyme
preference. This is in line with the fact that all characterized
Type I BVMOs are highly selective for NADPH, and all
contain a lysine or arginine at this position. By saturation
mutagenesis it was probed which mutation would give the
highest activitywithNADHforHAPMO. Introduction of a
phenylalanine gives the best result in terms of catalytic
efﬁciency, as it was increased sevenfoldwhen comparedwith
WT-HAPMO. The highest kcat value with NADH (5.1 s
)1)
was obtained with the K439N variant. Apparently, relat-
ively bulky residues have to replace the lysine residue to
retain productive coenzyme binding.
Fig. 4. Speciﬁc activities with NADH for the clones from the K439X
library. The selected clones are indicated with arrows. The unbroken
and dotted lines indicate the range of wild-type (WT) and K439A
activities found, respectively.
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It was found that Arg440 does not play a role in
coenzyme recognition, but instead is important for a speciﬁc
catalytic event. The tight binding of AADP+, and the
reduction byNADPHwithout detectable turnover, indicate
that Arg440 is involved in facilitating a reaction step after
the reduction of the FAD cofactor. A possible role for this
residue could be the stabilization of the ﬂavin–peroxide
intermediate formed upon reaction of the reduced FAD
with molecular oxygen. The role of Arg440 might also
resemble the function of Arg66 in human glutathione
reductase where it is postulated that this residue has
electrostatic interactions with the formed NADP+ so that
it is repelled from the isoalloxazine environment [47].
However, mutant R440A does not show tighter binding
of NADP+ compared to WT-HAPMO (data not shown).
The results obtained show that HAPMO is able to
distinguish between NADPH, NADP+ and AADP+. The
differences in afﬁnity must be related to the properties of the
nicotinamide moiety. The reduced nicotinamide ring of
NADPH is neutral, nonaromatic and slightly shaped into a
boat nonplanar conformation [48]. Typically, the carboxa-
mide side-chain is bound in the enzyme active site via one or
more hydrogen bonds [49]. Upon oxidation, the nicotina-
mide ring becomes positively charged and aromatic. This
change could inﬂuence the binding properties of coenzyme
to the enzyme and would therefore explain why NADP+
binds with such low afﬁnity to HAPMO. Similar results
have been observed with dihydrofolate reductase, which
binds NADPH much more tightly compared to NADP+
[50]. What remains obscure is why, in contrast to HAPMO,
CHMO is able to bind NADP+ relatively tightly, with a
Kd of 32 lM [40]. NADP
+ has also been shown to be
a competitive inhibitor to NADPH for CHMO, with a
reported Ki of 38 lM [51]. However, we have found that
NADP+ is not an effective inhibitor for HAPMO. The
apparent differences in NADP+ binding will only be
resolved when more structural information on BVMOs
becomes available. The remarkable difference between the
binding of NADP+ and AADP+ by HAPMO shows that
the side-chain of the nicotinamide ring plays a delicate role.
It appears that NADP+, having a relatively bulky carbox-
amide side-chain at the nicotinamide ring, is sterically
hindered to bind properly, while AADP+, containing an
amine side-chain, is able to bind tightly. Comparable studies
with NADP+ analogues on the glutamate synthase b
subunit also showed that the size of the substituent at the
3¢ position determines the strength of ligand binding [52]. A
major part of the HAPMO sequence (residues 143–339)
shares 23% sequence identity with TrxR [24], suggesting
that the structure of Type I BVMOs will, to some extent,
share structural features with this FAD-containing
NADPH-dependent oxidoreductase. The involvement of
Arg339 in NADPH recognition, and the efﬁcient binding of
AADP+, are in agreement with this hypothesis. Inspection
of the TrxR structure complexed with AADP+ hints to a
possible reason for the extremely tight binding of the
NADP+ analog. The structure reveals a hydrogen bond
between the 3-amine group of the coenzyme analog and the
O4 of the isoalloxazine ring of the ﬂavin cofactor, which
would speciﬁcally promote AADP+ binding. Such a
ligand–cofactor interaction is in line with the observation
that another Type I BVMO, showing relatively low
sequence identity with HAPMO (24%), is also efﬁciently
inhibited by AADP+ [53]. The homology of HAPMOwith
TrxR also suggests that NADPH binds on the re side of the
ﬂavin. This is in line with the ﬁnding ofManstein et al., that
NADPH also binds at the re side of FAD in CHMO [54].
To conclude, we have identiﬁed two conserved basic
amino acids within the family of the Type I BVMOs that
account for their NADPH speciﬁcity. Furthermore, we
have constructed HAPMO mutants that display a signiﬁ-
cantly increased activity with NADH. However, owing to
the relatively high Km values, these enzyme variants are still
not efﬁcient enough to be used for biocatalytic applications.
For a complete reversal of the coenzyme speciﬁcity of a
Type I BVMO, in terms of catalytic efﬁciency, apparently a
greater number of residues need to be mutated. Elucidation
of a crystal structure of a Type I BVMO would greatly
facilitate such an enzyme redesign approach.
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